The broader access to antiretroviral drugs has led not only to considerable reductions in morbidity and mortality but, unfortunately, has increased the risk of virologic failure due to emergence and potential transmission of drug-resistant viruses. AIDS-tech will be a portable point of care diagnostic test that detects HIV drug resistance mutations in patient blood samples within 120 minutes, with an estimated sensitivity of 80-90% at an estimated cost of $50. A rechargeable battery (8-hour half-life) will be fitted to support a full day’s testing to use in field settings where access to electricity is limited. Results will be interpreted with a naked eye (observing color change on the strips), hence eliminating the need for computers and software. This will aid timely acquisition of resistance results and guide clinicians on which regime to start the patient and thus improve treatment outcome. It will also aid in the World Health Organization’s target to limit the number of patients with HIV.